➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Merck
Baxter
Express Scripts
Boehringer Ingelheim

Last Updated: April 10, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Danirixin

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Danirixin?

Danirixin is an investigational drug.

There have been 10 clinical trials for Danirixin. The most recent clinical trial was a Phase 2 trial, which was initiated on April 28th 2017.

The most common disease conditions in clinical trials are Lung Diseases, Chronic Disease, and Pulmonary Disease, Chronic Obstructive. The leading clinical trial sponsors are GlaxoSmithKline and [disabled in preview].

There are twenty-five US patents protecting this investigational drug and two hundred and eighty-nine international patents.

Recent Clinical Trials for Danirixin
TitleSponsorPhase
GSK1325756 Relative Bioavailability Study in Healthy Elderly SubjectsGlaxoSmithKlinePhase 1
Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)GlaxoSmithKlinePhase 2
A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)GlaxoSmithKlinePhase 2

See all Danirixin clinical trials

Clinical Trial Summary for Danirixin

Top disease conditions for Danirixin
Top clinical trial sponsors for Danirixin

See all Danirixin clinical trials

US Patents for Danirixin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Danirixin   Start Trial Inhalable pharmaceutical compositions iCeutica Pty Ltd. (Iluka, WA, AU)   Start Trial
Danirixin   Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Start Trial
Danirixin   Start Trial Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators Pfizer Inc. (New York, NY)   Start Trial
Danirixin   Start Trial JAK inhibitors containing a 4-membered heterocyclic amide THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   Start Trial
Danirixin   Start Trial Fused imidazo-piperidine JAK inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   Start Trial
Danirixin   Start Trial Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN)   Start Trial
Danirixin   Start Trial Therapeutic compounds and compositions, and methods of use thereof Genentech, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Danirixin

Drugname Country Document Number Estimated Expiration Related US Patent
Danirixin Australia AU2013227351 2032-02-28   Start Trial
Danirixin Australia AU2016202881 2032-02-28   Start Trial
Danirixin Australia AU2017213466 2032-02-28   Start Trial
Danirixin Canada CA2865702 2032-02-28   Start Trial
Danirixin China CN104703584 2032-02-28   Start Trial
Danirixin China CN107875127 2032-02-28   Start Trial
Danirixin European Patent Office EP2819645 2032-02-28   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Merck
Baxter
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.